phenylpropanolamine
Trade name: Propadrine
Approved
Jan 4, 1984
(+)-Phenylpropanolamine is an enantiomer of propanolamine. The substance has low adrenergic activity and exerts measurable physiological effect only at high doses, which were lethal to experimental animals tested. Phenylpropanolamine belongs to the sympathomimetic amine class of drugs and is structurally related to ephedrine. The effects of phenylpropanolamine are largely the result of alpha-adrenergic agonist activity resulting from both direct stimulation of adrenergic receptors and release of neuronal norepinephrine. Phenylpropanolamine containing products has been withdrawn by FDA due to the association of phenylpropanolamine use with increased risk of hemorrhagic stroke. — NCATS
Clinical trial activity
5 trials · 4 clinical orgs · 4 marketing orgs
Earliest trial started Jul 1, 2013 (NCT01895400)
Timeline
Indications
Approved for
Mechanism of action
- Alpha-1a adrenergic receptorAGONIST
ADRA1A agonist
- Norepinephrine transporterRELEASING AGENT
SLC6A2 releasing agent
Combination products
codamine
with hydrocodone
cold capsule v
with dexchlorpheniramine maleate
Also known as cold capsule iv
corsym
with chlorpheniramine
Approval history
- withdrawnJan 4, 1984
- approvedJun 1, 1938
Chemistry & pharmacology
SMILES
OS(O)(=O)=O.C[C@H](N)[C@H](O)C1=CC=CC=C1.C[C@H](N)[C@H](O)C2=CC=CC=C2- Mol. weight
- 400.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaPhenylpropanolamine ↗
- NCATSTQA3O9M79V ↗
- ChEMBLCHEMBL61006 ↗
- ChEMBLCHEMBL1201535 ↗
- ChEMBLCHEMBL1200695 ↗
Also known as
- 2-amino-1-phenylpropan-1-ol
- 2-amino-1-phenylpropan-1-ol
- dexatrim
- dexatrim
- dimotapp
- dimotapp l.a.
- eskornade
- eskornade
- fenilpropanolamina
- fenilpropanolamina
- norephedrin
- norephedrin
- norephedrine
- norephedrine
- norephedrine
- norephedrine hcl
- norephedrine hcl
- phenylpropanolamin
- phenylpropanolamin
- phenylpropanolamine
- phenylpropanolamine
- phenylpropanolamine
- phenylpropanolamine
- phenylpropanolamine
- phenylpropanolamine
- phenylpropanolamine
- phenylpropanolamine
- phenylpropanolamine
- phenylpropanolamine
- (+/-)-phenylpropanolamine
- phénylpropanolamine
- phénylpropanolamine
- phenylpropanolamine chloride
- phenylpropanolamine chloride
- phenylpropanolamine hcl
- phenylpropanolamine hcl
- phenylpropanolamine hcl
- phenylpropanolamine hydrochloride
- phenylpropanolamine hydrochloride
- phenylpropanolamine hydrochloride
- phenylpropanolamine polistirex
- phenylpropanolamine polistirex
- phenylpropanolaminum
- phenylpropanolaminum
- p-hydroxyamphetamine
- p-hydroxyamphetamine
- ppa
- procol
- procol
- propadrine
- propadrine
- propadrine
- propagest
- propagest
- renexin
- sine-off
- sine-off
- triogesic
- triominic
- β-hydroxyamphetamine
- β-hydroxyamphetamine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05445895 | Phase 4 | Oct 31, 2022 | SK Chemicals |
| NCT05906199 | Phase 4 | Jul 28, 2021 | SK Chemicals |
| NCT03318276 | Phase 3 | Feb 20, 2017 | SK Chemicals, Yonsei University |
| NCT02625714 | Phase 1 | Jun 1, 2015 | Dong-A University, SK Chemicals |
| NCT01895400 | Phase 3 | Jul 1, 2013 | SK Chemicals, University of Ulsan |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SK Chemicals | For profit | 5 | 4 | 3 | 2013 |
| Dong-A University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Ulsan | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Yonsei University | Academic/Hospital | 1 | 0 | 1 | 2017 |